# US 11,998,546 B2 · Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,998,546 B2
- Document ID: US11998546B2
- Status: Granted
- Kind: B2
- Application number: 16/344,453
- Filed: 2017-10-27
- Published: 2019-10-24
- Granted: 2024-06-04
- Earliest claimed: 2016-10-28
- Assignees: Acetylon Pharmaceuticals, Inc.
- Applicants: Acetylon Pharmaceuticals, Inc.
- Inventors: Pengyu Huang; Steven Quayle
- Web page: https://patentgrep.com/patent/US11998546B2

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/426: 1,3-Thiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an epothilone, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

## Claims

### Claim 1

A method for treating ovarian cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of
(a) a histone deacetylase 6 (HDAC6) inhibitor, wherein the HDAC6 inhibitor is:
or a pharmaceutically acceptable salt thereof; or
or a pharmaceutically acceptable salt thereof; and
(b) an epothilone selected from the group consisting of epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, and epothilone F, or pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HDAC6 inhibitor is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HDAC6 inhibitor is:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the epothilone is epothilone B having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is resistant or refractory to treatment with paclitaxel.

### Claim 6 (depends on 1)

The method of claim 1, wherein the HDAC6 inhibitor and the epothilone are administered at approximately the same time.

### Claim 7 (depends on 1)

The method of claim 1, wherein the HDAC6 inhibitor and the epothilone are administered at different times.